Baxalta

ADYNOVATE

Manufacturer:

Baxalta

Adynovate HCPCS:

J7207

HCPCS Code Descriptor:

Injection, factor viii, (antihemophilic factor, recombinant), pegylated, 1 i.u.

Category:

J Code

Adynovate NDCs:

00944-4627-01, 00944-4628-01, 00944-4626-01, 00944-4625-01, 00944-4624-01, 00944-4622-01, 00944-4623-01

Primary Type:

Hematology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Adynovate:

ADYNOVATE is a Hematology drug manufactured by Baxalta and administered via the Intravenous route of administration. The J Code: J7207 is aligned to the drug ADYNOVATE.

ADYNOVATE is an antihemophilic factor commonly used for routine prevention and on-demand treatment of bleeding episodes as well as bleeding management in a perioperative setting for hemophilic patients. It is a polyethyleneglycolated (PEGylated) form of recombinant Factor VIII that temporarily replaces Factor VIII in patients with hemophilia A. The PEGylation of recombinant Factor VIII reduces binding of ADYNOVATE (J7207) to the Factor VIII clearance factor and increases the life of ADYNOVATE in the body. ADYNOVATE is indicated for use in children and adults with hemophilia A. Patient assistance for this medication can be found through Takeda’s Hematology Support Center.

ACCESS PRICING AND MORE BY REGISTERING

J7207 Added Date:

January 1, 2017

J7207 Effective Date:

January 1, 2017

J7207 Termination Date:

HCPCS Active

Adynovate billing and coding information can be found through Baxalta at the link below:
Adynovate patient assistance information can be found through Takeda Patient Support at the URL: https://www.hematologysupport.com/financial-assistance#about-pap
ADYNOVATE prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for ADYNOVATE. Please check back in a few weeks.